Solomon. DELIVER Design Manuscript
Details of the DELIVER study design and statistical analysis
Solomon. DELIVER primary Manuscript
DELIVER primary results manuscript
Vaduganathan. SGLT2 Meta-analysis
Meta-analysis of DELIVER, EMPEROR-Preserved and other SGLT2 trials
Myhre. NT-proBNP in DELIVER
Influence of NT-proBNP on outcomes in DELIVER
Butt. Atrial fibrillation in DELIVER
Influence of atrial fibrillation on outcomes and effectiveness of dapagliflozin in DELIVER
Peikert. Age and Effectiveness and Safety of Dapagliflozin in DELIVER
Influence of Age on the safety and effectiveness of dapagliflozin in DELIVER
Desai. DELIVER DAPA-HF Cause of Death
Mode of death across the spectrum in ejection fraction in DAPA-HF and DELIVER
Lam. Solomon. On my mind...
Discussion of why the results of DELIVER suggest that SGLT2 inhibitors behave differently from other therapies in Heart Failure
McCausland. Renal Outcomes in DELIVER
Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fractio
Wang. Sex Differences in DAPA-HF and DELIVER
Effect of Dapagliflozin according to sex across the EF spectrum
Kosiborod. Effect of Dapagliflozin on Health Status and Quality of Life
Effect of Dapagliflozin on Health Status and Quality of Life in Mildly Reduced or Preserved Ejection Fraction
Talha. Population-Level Implications of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Preserved Ejection Fraction in the US
Population-Level Implications of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Preserved Ejection Fraction in the US
Butt. Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum
Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum
Vaduganathan. All-Cause Hospitalizations
Dapagliflozin and All-Cause Hospitalizations in Patients With Heart Failure With Preserved Ejection Fraction
Solomon. DELIVER Baseline Manuscript
Detailed baseline characteristics of DELIVE
Jhund. DAPA-HF DELIVER pooled
Prespecified pooled analysis of DELIVER and DAPA-HF
Cunningham. Dapagliflozin in hospitalized or recently hospitalized patients
Effect of dapagliflozin in hospitalized or recently hospitalized patients with mildly reduced or preserved ejection fraction
Adamson. BMI and Dapagliflozin in DELIVER
Influence of BMI on effectiveness of dapagliflozin in DELIVER
Butt. Frailty in DELIVER
Effect of frailty on effectiveness and safety of dapagliflozin in DELIVER
Ostrominski. NYHA in DELIVER
NYHA Class and effectiveness of Dapagliflozin and effect of dapagliflozin on NYHA class in DELIVER
Vaduganathan. Time to Clinical Benefit
Time to clinical benefit in DELIVER
Selvaraj. BP in DELIVER
Effect of blood pressure on efficacy of dapagliflozin and influence of dapagliflozin on blood pressure in DELIVER
Inzucchi. DELIVER Diabetes and Pre-Diabetes
Effect of Dapagliflozin on Patients with Diabetes or Pre-Diabetes and Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Vardeny. Dapagliflozin in Heart Failure with Improved Ejection Fraction
Effect of Dapagliflozin in patients with heart failure with improved ejection fraction
Yang. Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan
Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
Butt. Dapagliflozin and Gout
Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid–Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout
A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER
